JP2014507422A5 - - Google Patents

Download PDF

Info

Publication number
JP2014507422A5
JP2014507422A5 JP2013551360A JP2013551360A JP2014507422A5 JP 2014507422 A5 JP2014507422 A5 JP 2014507422A5 JP 2013551360 A JP2013551360 A JP 2013551360A JP 2013551360 A JP2013551360 A JP 2013551360A JP 2014507422 A5 JP2014507422 A5 JP 2014507422A5
Authority
JP
Japan
Prior art keywords
alkyl
group
formula
substituted
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013551360A
Other languages
English (en)
Japanese (ja)
Other versions
JP6000283B2 (ja
JP2014507422A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/022847 external-priority patent/WO2012106188A1/en
Publication of JP2014507422A publication Critical patent/JP2014507422A/ja
Publication of JP2014507422A5 publication Critical patent/JP2014507422A5/ja
Application granted granted Critical
Publication of JP6000283B2 publication Critical patent/JP6000283B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013551360A 2011-01-31 2012-01-27 Hiv成熟阻害剤としてのc−3修飾ベツリン酸誘導体のc−28アミン Expired - Fee Related JP6000283B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161437870P 2011-01-31 2011-01-31
US61/437,870 2011-01-31
PCT/US2012/022847 WO2012106188A1 (en) 2011-01-31 2012-01-27 C-28 amines of c-3 modified betulinic acid derivatives as hiv maturation inhibitors

Publications (3)

Publication Number Publication Date
JP2014507422A JP2014507422A (ja) 2014-03-27
JP2014507422A5 true JP2014507422A5 (enExample) 2015-02-26
JP6000283B2 JP6000283B2 (ja) 2016-09-28

Family

ID=45567146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013551360A Expired - Fee Related JP6000283B2 (ja) 2011-01-31 2012-01-27 Hiv成熟阻害剤としてのc−3修飾ベツリン酸誘導体のc−28アミン

Country Status (19)

Country Link
US (1) US8748415B2 (enExample)
EP (1) EP2670764B1 (enExample)
JP (1) JP6000283B2 (enExample)
CN (1) CN103339141B (enExample)
BR (1) BR112014010105A2 (enExample)
CA (1) CA2826257A1 (enExample)
CY (1) CY1116989T1 (enExample)
DK (1) DK2670764T3 (enExample)
EA (1) EA023578B1 (enExample)
ES (1) ES2552512T3 (enExample)
HR (1) HRP20151212T1 (enExample)
HU (1) HUE026371T2 (enExample)
MX (1) MX2013008359A (enExample)
PL (1) PL2670764T3 (enExample)
PT (1) PT2670764E (enExample)
RS (1) RS54352B1 (enExample)
SI (1) SI2670764T1 (enExample)
SM (1) SMT201500303B (enExample)
WO (1) WO2012106188A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2758419B8 (en) 2011-09-21 2017-04-19 VIIV Healthcare UK (No.5) Limited Novel betulinic acid derivatives with antiviral activity
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) * 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
RU2519133C1 (ru) * 2012-11-09 2014-06-10 Леонид Леонидович Клопотенко Мазь, содержащая инкапсулированную тритерпеновую кислоту или ее производные
RU2516952C1 (ru) * 2012-11-09 2014-05-20 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инкапсулированную тритерпеновую кислоту или ее производные
CN103214543B (zh) * 2012-12-25 2015-09-02 中国人民解放军海军医学研究所 新山楂酸衍生物、其制备方法及其在抗肿瘤药物中的应用
EA027371B1 (ru) * 2013-02-06 2017-07-31 Бристол-Майерс Сквибб Компани C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
BR112015019590A2 (pt) * 2013-02-25 2017-07-18 Bristol Myers Squibb Co derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
MX374543B (es) 2014-04-11 2025-03-06 Viiv Healthcare Uk No 4 Ltd Triterpenoides con actividad inhibidora de la maduración del virus de inmunodeficiencia humana, sustituidos en la posición 3 con un anillo no aromático que lleva un sustituyente haloalquilo.
US9920090B2 (en) * 2014-06-19 2018-03-20 VIIV Healthcare UK (No.5) Limited Betulinic acid derivatives with HIV maturation inhibitory activity
RU2017118576A (ru) 2014-11-14 2018-12-14 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД C-17-арил-замещённые аналоги бетулиновой кислоты
AU2015346303B2 (en) * 2014-11-14 2018-03-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
US9914747B2 (en) 2014-11-14 2018-03-13 VIIV Healthcare UK (No.5) Limited Extended betulinic acid analogs
JP2018512433A (ja) * 2015-04-14 2018-05-17 ヴィーブ ヘルスケア ユーケー(ナンバー4)リミテッド Hiv成熟阻害剤の製造方法
KR20180028534A (ko) 2015-07-28 2018-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
RU2018105352A (ru) 2015-07-28 2019-08-29 ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед Производные бетулина для предупреждения или лечения ВИЧ-инфекций
RU2018112958A (ru) 2015-09-24 2019-10-28 ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед Соединения с ингибирующей созревание ВИЧ активностью
CN108699103A (zh) 2016-01-20 2018-10-23 葛兰素史克知识产权第二有限公司 具有hiv成熟抑制活性的羽扇烷类的胺衍生物
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
EP3478703A1 (en) * 2016-06-30 2019-05-08 ViiV Healthcare UK (No.5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
EP3681507B8 (en) * 2017-09-13 2024-03-13 Emmyon, Inc. Ursolic acid morpholine and diethanolamine salts
CN111417384A (zh) 2017-09-14 2020-07-14 菲尼克斯生物技术公司 用于治疗神经系统病况的方法和改进的神经保护性组合物
CA3075729A1 (en) 2017-09-14 2019-03-21 Phoenix Biotechnology, Inc. Use of oleandrin to treatn viral infection
JP7436385B2 (ja) 2018-04-24 2024-02-21 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド Hiv成熟阻害活性を有する化合物
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
US10343997B1 (en) 2018-12-04 2019-07-09 King Saud University Ursolic acid derivatives
KR20220151038A (ko) 2020-03-31 2022-11-11 피닉스 바이오테크놀러지 인코포레이티드. 코로나바이러스 감염 예방를 위한 조성물
EP4295854A3 (en) 2020-03-31 2024-04-03 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US20050014730A1 (en) 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
EP1730163A4 (en) 2004-03-17 2009-12-30 Panacos Pharmaceuticals Inc Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
CN101142227A (zh) * 2004-11-12 2008-03-12 帕纳克斯医药公司 新颖的桦木醇衍生物、其制备和其用途
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
WO2012106190A1 (en) * 2011-01-31 2012-08-09 Bristol-Myers Squibb Company C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
JP2011511812A (ja) 2008-02-14 2011-04-14 バイロケム ファーマ インコーポレイテッド 新規17βルパン誘導体
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
BR112012030810A2 (pt) * 2010-06-04 2019-09-24 Bristol-Myers Squibb Company "c-28 amidas de derivados de ácido c-3 betulínico modificados como inibidores de maturação de hiv"
CA2801487C (en) * 2010-06-04 2017-12-05 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors

Similar Documents

Publication Publication Date Title
JP2014503595A5 (enExample)
JP2015510515A5 (enExample)
JP2013527243A5 (enExample)
JP2016509062A5 (enExample)
ES2552512T3 (es) Aminas C-28 de derivados de ácido betulínico modificado en C-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana
AR074165A1 (es) Antagonistas de heteroalquilo de receptores de prostaglandina d2 y composiciones farmaceuticas
JP2019504104A5 (enExample)
HRP20200538T1 (hr) Derivati pirimidina za liječenje virusnih infekcija
HRP20130976T1 (hr) Karbonilaminopirolopirazoli, potentni inhibitori kinaza
JP2017505314A5 (enExample)
RU2013116801A (ru) Ингибиторы notum пектинацетилэстеразы и способы их применения
CY1119727T1 (el) Ενωσεις και συνθεσεις για τη θεραπεια παρασιτικων νοσων
JP2018513150A5 (enExample)
JP2020530487A5 (enExample)
RU2013121785A (ru) Новые противовирусные соединения
WO2014172188A3 (en) 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
AR083058A1 (es) Compuestos de estructura de imidazotriazinona
HRP20200995T1 (hr) 19-nor neuroaktivni steroidi za metode liječenja
JP2011526924A5 (enExample)
EA201291301A1 (ru) Производные 2-хинолинилуксусной кислоты в качестве противовирусных соединений против вич
RU2015143990A (ru) Трициклические соединения в качестве ингибиторов иммуносупрессии, опосредуемой метаболизированием триптофана
TN2016000090A1 (en) Substituted quinolizine derivatives useful as hiv integrase inhibitors.
JP2018510139A5 (enExample)
JP2015134763A5 (enExample)
JP2016526558A5 (enExample)